Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab and Venetoclax in R/R DLBCL
NCT02987400Phase 2Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Jan 2017
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in diffuse large B-cell lymphoma (DLBCL), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Primary endpoint: Clinical activity and tolerability at 9 weeks. Started Jan 2017; status: completed.
02
Drugs
venetoclax
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02987400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987400.